HOWL Latest Report

Financial Performance

Werewolf (stock code: HOWL) faced significant operating challenges in 2024. The total operating revenue at December 31, 2024 was negative, indicating poor operating conditions for the company in that year. The data showed a significant decline compared to the total operating revenue in 2023, affecting overall profitability.

Key Financial Data

1. The operating revenue in 2024 was -20348000 yuan, a significant decrease from -12962000 yuan in 2023, indicating serious challenges in sales or business expansion.

2. The research and development expenses in 2024 were 15727000 yuan, a significant increase from 9649000 yuan in 2023, which may cause short-term financial pressure and affect operating revenue.

3. Intensified market competition may have led to a decrease in sales revenue, and Werewolf faces pressure from competitors in the same industry.

4. Macroeconomic uncertainty may affect consumer purchasing power, which in turn affects the company's operating revenue.

5. Marketing, sales, and general management expenses in 2024 slightly decreased but still reached 4621000 yuan, indicating problems in cost control and operational efficiency.

Peer Comparison

1. Industry-wide analysis: In the current industry environment, many companies face challenges in revenue decline, especially in the technology and consumer goods sectors due to market demand fluctuations and supply chain issues. Werewolf's revenue decline reflects the general operating difficulties in the industry.

2. Peer evaluation analysis: Compared to peers in the same industry, Werewolf's revenue performance is relatively poor. Many competitors achieved revenue growth in 2024, indicating that Werewolf is at a disadvantage in the market competition and may need to reassess its market strategy and product positioning.

Conclusion

Werewolf's operating revenue declined significantly in 2024, mainly affected by intensified market competition and macroeconomic uncertainty. The increase in research and development expenses and management efficiency issues may further exacerbate its financial difficulties. Overall, these factors indicate that Werewolf needs to take urgent measures to improve its operating conditions.

Opportunities

1. Through optimizing its product line and market strategy, Werewolf may enhance its market competitiveness.

2. In terms of research and development, the clinical trials of WTX-124 and WTX-330 may bring new business opportunities.

3. Leveraging changes in market demand, Werewolf can adjust its business direction to adapt to new market trends.

Risks

1. Continuous revenue decline may lead to cash flow problems, affecting the company's operating ability.

2. Increased research and development investment may add financial burden in the short term, affecting profitability.

3. Competitors' strong market performance may put Werewolf under greater market pressure.